Methylprednisolon acis 1000 mg Pulver und Lösungsmittel zur Herstellung einer Injektions- bzw. Infusionslösung

DRUG3 trials

Sponsors

Kezar Life Sciences Inc., Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V., F. Hoffmann-La Roche AG

Conditions

Autoimmune diseaseRelapsing-Remitting Multiple SclerosisSporadic Amyotrophic Lateral Sclerosis

Phase 2

B-cell depletion for the treatment of patients with amyotrophic lateral sclerosis (ALS) - A Randomized, Double-blind, Placebo controlled Pilot Study in Patients with Amyotrophic Lateral Sclerosis for the Evaluation of Efficacy and Safety of B-Cell Depletion with Rituximab (ABCD)

RecruitingCTIS2022-502743-35-00

Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.Sporadic Amyotrophic Lateral Sclerosis

Start: 2024-04-22Target: 52Updated: 2025-12-19

A Phase 2b, Randomized, Controlled Double-blind, Multicenter Study Comparing the Efficacy and Safety of Zetomipzomib (KZR-616) 30 mg or 60 mg with Placebo in Patients with Active Lupus Nephritis

CompletedCTIS2022-502227-22-00

Kezar Life Sciences Inc.Autoimmune disease

Start: 2023-10-25End: 2024-10-17Target: 82Updated: 2024-04-24

Phase 3

A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Active, not recruitingCTIS2023-506516-40-00

F. Hoffmann-La Roche AGRelapsing-Remitting Multiple Sclerosis

Start: 2022-02-11Target: 94Updated: 2025-10-01